Quick Answer
Edgewise Therapeutics, Inc. reported Net Income of -$167.79 million for fiscal year 2025.
Edgewise Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$167.79M | -25.4% |
| 2024 | -$133.81M | -33.6% |
| 2023 | -$100.16M | -48.1% |
| 2022 | -$67.64M | -58.0% |
| 2021 | -$42.81M | -150.0% |
| 2020 | -$17.12M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$40.67M | -19.2% | -12.6% |
| June 30, 2025 | -$36.12M | -14.7% | +11.5% |
| March 31, 2025 | -$40.80M | -43.0% | -19.5% |
| September 30, 2024 | -$34.13M | -32.7% | -8.4% |
| June 30, 2024 | -$31.50M | -46.7% | -10.4% |
| March 31, 2024 | -$28.52M | -24.9% | -10.9% |
| September 30, 2023 | -$25.71M | -46.9% | -19.8% |
| June 30, 2023 | -$21.47M | -33.6% | +6.0% |
- Edgewise Therapeutics, Inc. showed a decrease of -25.4% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Edgewise Therapeutics, Inc.’s net income has declined by 879.9% (from -$17.12 million to -$167.79 million).
- The most recent figure is from Edgewise Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: